GlassScriptPhysician profile
Christopher Carey
NPI 1932604022
$16,104.66
in general payments reported to CMS, 2019-2025
58 companies · $4,410 in 2025
The $4,410 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $228 · 2021: $443 · 2022: $1,800 · 2023: $4,268 · 2024: $4,493 · 2025: $4,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $40.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,129.54 |
| Education | $40.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,070.87 | 2022-2025 | Botox, Ubrelvy, Duopa |
| Ucb, INC. | $1,159.20 | 2022-2025 | Briviact, Zilbrysq, Nayzilam |
| Alexion Pharmaceuticals, INC. | $1,127.00 | 2019-2025 | Ultomiris, Soliris |
| Acadia Pharmaceuticals INC | $1,023.73 | 2019-2025 | Nuplazid |
| Sk Life Science, INC. | $824.80 | 2022-2025 | |
| Eisai INC. | $783.26 | 2020-2025 | |
| Pfizer INC. | $743.26 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $705.29 | 2023-2025 | |
| Emd Serono, INC. | $599.08 | 2020-2025 | Mavenclad |
| Lilly USA, LLC | $511.54 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Biogen, INC. | $506.34 | 2021-2025 | Vumerity, Tysabri, Skyclarys |
| Amgen INC. | $487.47 | 2020-2025 | Uplizna |
| Neurocrine Biosciences, INC. | $486.87 | 2022-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $457.32 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $452.14 | 2022-2025 | Vyepti, Rexulti |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Carey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.